An unusual legal battle over a biotech startup's IPO plans escalated to another level on Valentine's Day, according to two ...

Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...

FDA denies Invivyd's EUA expansion for Pemgarda in Covid treatment while BioCryst reports positive Orladeyo data. AN2 changes endpoint, OS Therapies seeks partners & Eyenovia restructures.

Amgen to invest $200M in new Hyderabad tech center through 2025, focusing on AI for drug development. Site opened Monday with ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

With help from its $43 billion Seagen merger, Pfizer will contribute its antibody-drug conjugates to Summit Therapeutics' ...

So far, only 22% of life sciences organizations have adopted AI at scale, yet 86% of healthcare and life sciences leaders ...

Pharma executives at PhRMA Forum avoid discussing controversial Trump administration health policies while praising him as ...

Pfizer CEO Albert Bourla supports Trump administration at PhRMA Forum, while CDC postpones vaccine advisory meeting. Atomwise names Steve Worland as CEO, and Biogen licenses Dravet drug.

The FDA on Friday approved Mirum Pharmaceuticals' Ctexli to treat adults with cerebrotendinous xanthomatosis (CTX), a rare, progressive and genetic disease.

Celia Witten, deputy director of the FDA's Center for Biologics Evaluation and Research, has left the FDA, adding to a wave of departures at the agency and across the federal health infrastructure as ...